Skip to main content
. 2020 May 22;15(8):1146–1154. doi: 10.2215/CJN.11650919

Figure 4.

Figure 4.

A significantly higher incidence of ischemic stroke or MI was seen in the subgroup of patients treated with the reduced apixaban dose but not in patients who received the standard apixaban dose, compared with patients who did not receive any anticoagulants. Adjusted HRs are depicted. Death was considered as competing risk. Apixaban prescription was examined as a time-varying covariate.